Greenwich LifeSciences Inc’s filing revealed that its CEO and CFO Patel Snehal acquired Company’s shares for reported $91848.0 on Dec 31 ’25. In the deal valued at $21.36 per share,4,300 shares were bought. As a result of this transaction, Patel Snehal now holds 5,599,402 shares worth roughly $162.49 million.
Then, Patel Snehal bought 2,900 shares, generating $63,017 in total proceeds. Upon buying the shares at $21.73, the CEO and CFO now owns 5,595,102 shares.
Before that, Patel Snehal bought 4,100 shares. Greenwich LifeSciences Inc shares valued at $51,742 were divested by the CEO and CFO at a price of $12.62 per share. As a result of the transaction, Patel Snehal now holds 5,592,202 shares, worth roughly $162.29 million.
Noble Capital Markets initiated its Greenwich LifeSciences Inc [GLSI] rating to an Outperform in a research note published on August 20, 2025; the price target was $45. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early September with a ‘”a Buy”‘ rating.
Price Performance Review of GLSI
On Tuesday, Greenwich LifeSciences Inc [NASDAQ:GLSI] saw its stock jump 8.16% to $29.02. Over the last five days, the stock has gained 41.35%. Greenwich LifeSciences Inc shares have risen nearly 134.41% since the year began. Nevertheless, the stocks have risen 38.12% over the past one year.
How much short interest is there in Greenwich LifeSciences Inc?
A steep rise in short interest was recorded in Greenwich LifeSciences Inc stocks on 2025-12-31, growing by 59376.0 shares to a total of 1.67 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 1.61 million shares. There was a rise of 3.56%, which implies that there is a positive sentiment for the stock.
